Valganciclovir use among commercially and Medicaid-insured infants with congenital CMV infection in the United States, 2009–2015
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Valganciclovir use among commercially and Medicaid-insured infants with congenital CMV infection in the United States, 2009–2015

Filetype[PDF-237.25 KB]


Details Supporting Files You May Also Like

Details:

  • Alternative Title:
    Clin Ther
  • Personal Author:
  • Description:
    Purpose

    To assess clinical characteristics and trends in valganciclovir use among infants diagnosed with congenital cytomegalovirus (CMV) disease in the United States.

    Methods

    We analyzed 2009–2015 medical claims from Truven Health MarketScan® Commercial Claims and Encounters and Medicaid databases. We identified infants with a live birth code in the first claim who were enrolled for at least 45 days. Among infants diagnosed with congenital CMV disease, identified by an ICD-9-CM or ICD-10-CM code of congenital CMV infection or CMV disease within 45 days of birth, we assessed codes for CMV-associated clinical condition within the same period, and hearing loss and valganciclovir claims within the first 180 days.

    Findings

    In the commercial and Medicaid databases, we identified 257 (2.5/10,000) and 445 (3.3/10,000) infants diagnosed with congenital CMV disease, respectively, among whom 135 (53%) and 282 (63%) had ≥1 CMV-associated condition, 30 (12%) and 32 (7%) had hearing loss, and 41 (16%) and 78 (18%) had valganciclovir claims. Among infants with congenital CMV disease who had valganciclovir claims, 37 (90%) among commercially-insured infants and 68 (87%) among Medicaid-insured infants had ≥1 CMV-associated condition and/or hearing loss. From 2009 to 2015, the proportion with valganciclovir claims increased from 0% to 29% among commercially-insured infants and from 4% to 37% among Medicaid-insured infants (p<0.0001).

    Implications

    During 2009–2015, there was a strong upward trend in valganciclovir claims among insured infants who were diagnosed with congenital CMV disease, the majority of whom had CMV-associated conditions and/or hearing loss.

  • Subjects:
  • Source:
    Clin Ther. 40(3):430-439.e1.
  • Pubmed ID:
    29397198
  • Pubmed Central ID:
    PMC5857424
  • Document Type:
    Journal Article
  • Funding:
    CC999999/Intramural CDC HHS/United States
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov